Rhenman & Partners Asset Management’s TG Therapeutics TGTX Stock Holding History

Rhenman & Partners Asset Management’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-73,250	Closed	-$2.18M	–	102
2025 Q4	$2.18M	Sell	73,250 -19,750	-21%	-$645K	0.2%	86
2025 Q3	$3.36M	Sell	93,000 -22,000	-19%	-$725K	0.37%	70
2025 Q2	$4.14M	Sell	115,000 -62,500	-35%	-$2.33M	0.52%	56
2025 Q1	$7M	Sell	177,500 -85,000	-32%	-$2.86M	0.8%	39
2024 Q4	$7.9M	Buy	262,500 +91,000	+53%	+$2.61M	0.81%	46
2024 Q3	$4.01M	Sell	171,500 -42,000	-20%	-$917K	0.33%	72
2024 Q2	$3.8M	Buy	213,500 +90,000	+73%	+$1.44M	0.36%	64
2024 Q1	$1.88M	Sell	123,500 -36,500	-23%	-$581K	0.18%	79
2023 Q4	$2.73M	Hold	160,000	–	–	0.27%	69
2023 Q3	$1.34M	Buy	160,000 +105,000	+191%	+$1.46M	0.14%	79
2023 Q2	$1.37M	Buy	+55,000	New	+$1.42M	0.14%	79

Other funds holding TGTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Rhenman & Partners Asset Management's TGTX Position: Q1 2026 in Review

Rhenman & Partners Asset Management sold out of TG Therapeutics (TGTX) in Q1 2026, closing a stake of 73,250 shares — an estimated $2.18M sold.

Rhenman & Partners Asset Management first reported a position in TGTX in Q2 2023 and held it in 11 quarters. The position peaked at $7.9M in Q4 2024. 363 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

Rhenman & Partners Asset Management reported no remaining TG Therapeutics position as of Q1 2026 after selling out during the quarter.
Rhenman & Partners Asset Management sold 73,250 TG Therapeutics shares in Q1 2026, an estimated $2.18M.
Rhenman & Partners Asset Management first reported a position in TG Therapeutics in Q2 2023 and held it in 11 quarters.
Rhenman & Partners Asset Management's TG Therapeutics position peaked at $7.9M in Q4 2024.
363 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2026, filed 14 May 2026.